Valuation: MacroGenics, Inc.

Market Cap 285M 249M 230M 212M 400M 27.48B 409M 2.75B 1.08B 13.46B 1.07B 1.05B 46.34B P/E 2026 *
-6.69x
P/E 2027 * -2.94x
Enterprise Value 285M 249M 230M 212M 400M 27.48B 409M 2.75B 1.08B 13.46B 1.07B 1.05B 46.34B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 3.03x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day+8.98%
1 week+3.70%
Current month-2.81%
1 month+13.38%
3 months+29.77%
6 months+161.05%
Current year+178.88%
1 week 4
Extreme 4.005
4.54
1 month 4
Extreme 4
5.08
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
28.09
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/5/26 Free

Founder

25,750 0.0405%
19/5/26 Free

Director

25,750 0.0405%
19/5/26 Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+8.98%+3.70%+191.56%-11.09% 262M
-7.17%-4.39%+45.51%+79.00% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+0.80%-6.31%+3.98%+423.29% 23.29B
-0.09%-0.01%-17.62%-14.67% 23.15B
-5.95%-2.58%+30.67%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+168.44%+306.37% 16.09B
-6.91%-5.83%+26.53%+636.97% 15.93B
+0.43%-1.03%+24.63%+191.40% 14B
Average -1.60%+0.25%+55.85%+164.31% 24.07B
Weighted average by Cap. -2.91%-0.73%+40.75%+144.62%

Financials

2026 *2027 *
Net sales 164M 144M 133M 122M 230M 15.83B 235M 1.58B 623M 7.75B 617M 604M 26.69B 94.26M 82.37M 76.01M 70.06M 132M 9.08B 135M 909M 357M 4.45B 354M 346M 15.3B
Net income -18.31M -16M -14.76M -13.61M -25.65M -1.76B -26.22M -176M -69.4M -863M -68.75M -67.24M -2.97B -127M -111M -102M -94.43M -178M -12.23B -182M -1.22B -482M -5.99B -477M -467M -20.63B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
17/07/26 US$4.490 +8.98% 1,031,705
16/07/26 US$4.120 -4.63% 898,793
15/07/26 US$4.320 +0.70% 592,219
14/07/26 US$4.290 -4.67% 1,279,751
13/07/26 US$4.500 +3.93% 1,124,151
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.490USD
Average target price
6.750USD
Spread / Average Target
+50.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock